RS12672 mitra adhami 11 resizedClinical research trials are an integral part of the advancement in medicine for both the treatment and prevention of infectious diseases. These trials serve to discover whether or not a particular treatment or preventative is safe and effective. All new drugs and medical devices must go through the process of clinical trials before being approved, produced, and marketed for the general public; thus, it is ultimately our volunteers whom help us understand, prevent, and treat communicable diseases.

A common misconception about clinical research trials is that only people who are sick or have a disease participate in them. Clinical trials, however, need people from all types of backgrounds for studies, including those who are healthy and those who have an illness or disease. Healthy people may choose to participate because they know someone who is affected by a particular illness or disease, or they may participate for philanthropic reasons. Participants who are sick or have a disease may also want to help others; however, being in a clinical research trial provides them with a chance to receive a new treatment as well as additional medical care and attention specifically for their ailment.

No matter the reason for joining a clinical research trial, just remember: With your help, we can bring an end to many infectious diseases throughout the world! Be the change...

Click below to view our upcoming and currently enrolling research studies. For a printable Clinical Research Trial Guide, click here.
 
Anticipated Start: September 2018

Bavarian Nordic RSV is anticipated to be a Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of the Recobinant MVA-BN RSV vaccine after intranasal and intramuscular administration. RSV: Respiratory Syncytical Virus

Eligibility criteria has not yet been determined and will be updated as received.

If interested in placement on the wait-list for this study, please contact us via phone or the web.



The Flu Vaccine study is a Phase II study assessing safety, reactogenicity, and immunogenicity of a Sanofi Pasteur A/H7N9 inactivated Influenza vaccine administered intramuscularly with or without AS03 adjuvant.

This study is open to healthy, HIV-negative adults aged 19 to 64 years old. Females able to become pregnant must be willing to use a medically accepted contraceptive method from 30 days before first vaccination until 60 days after the last study vaccination. Participation in this study will last approximately 13 months with up to 8 scheduled clinic visits and 2-7 phone calls depending on which group you are randomized into.

Other inclusion criteria applies. Compensation is provided after enrollment for those who qualify. This study will enroll rapidly over a 12 week period once open. If interested in participating, it is recommended that you contact us before January to be placed on the wait-list for eligibility screening.

For more information or to be placed on the wait-list for this study, please contact us via phone or the web.

HVTN 108 is a Phase I/IIa HIV Prevention Trials Network clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59 or AS01B-adjuvanted clade C Env protein in various combinations, in healthy, HIV-uninfected adult participants.

This study is open to HIV-negative adults aged 18 to 40 who are, generally, in good health. Participation in this study will last approximately 1 year with 12 visits to the clinic. You cannot get HIV by participating in this clinical research trial.

Other inclusion criteria applies. Compensation is provided after enrollment for those who qualify.

For more information or to see if you are eligible for this study, please contact us via phone or the web.



HVTN 115 is a Phase I HIV Prevention Trials Network clinical trial to evaluate the safety and immunogenicity of EnvSeq-1 Envs (vaccine) adjuvanted with GLA-SE, administered alone or with DNA Mosaic-Tre env, in healthy, HIV-uninfected adult participants. This study will help determine optimal dosing to induce broadly neutralizing antibodies (bnAbs) against HIV-1.

This study is open to HIV-negative adults aged 18 to 50 who are, generally, in good health. Participation in this study will last approximately 18 months with 17 visits to the clinic. You cannot get HIV by participating in this clinical research trial.

Other inclusion criteria applies. Compensation is provided after enrollment for those who qualify.

For more information, placement on the wait-list, or to see if you are eligible for this study, please contact us via phone or the web.

Anticipated Start: April 2018

HVTN 121 is a Phase Ib open label clinical trial to evaluate HIV-1 neutralization on antibody breadth in response to HIV gp120 protein vaccine in HIV-uninfected adults with quiescent Systemic Lupus Erthematosus.

Additional information is not available at this time. Please check back later for updates and eligibility criteria.

Anticipated Start: February 2018

HVTN 124 is a Phase I clinical trial to evaluate the safety and immunogenicity of polyvalent env (A, B, C, AE)/gag (C) DNA and gp120 (A,B,C, AE) protein/GLA-SE HIV-1 vaccines as a prime-boost regimen or co-administered in repeated doses, in healthy, HIV-1-uninfected adult participants.

Additional information is not available at this time. Please check back later for updates and eligibility criteria.
 
Anticipated Start: February 2018

HVTN 125 is a Phase Ib randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and immunogenicity of the IHV01 protein vaccine primed and co-administered with HIV DNA CON-S env vaccine in healthy, HIV-1-uninfected adults.

Additional information is not available at this time. Please check back later for updates and eligibility criteria
.
 
Anticipated Start: January 2018

HVTN 127 is a multicenter, randomized, Phase I  clinical trial to evaluate the safety and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07 523LS), administered in multiple doses, routes and dosing schedules to healthy, HIV-uninfected adults. Additional information is not available at this time. Please check back later for updates and eligibility criteria.                 


Other inclusion criteria applies. Compensation is provided after enrollment for those who qualify.

For more information or to see if you are eligible for this study, please contact us via phone or the web.
                                                            
MTN 026 is a Phase I study.

The purpose of this study is to test the safety and pharmacokinetics of Dapivirine Gel (0.05%) when administered rectally to HIV negative adults. Dapivirine is a new drug that was shown in recent studies to be safe and to help protect against HIV infection when applied vaginally. Eligible volunteers will have 17 clinic visits during a 6 to 8 week period.
To qualify for this study, you need to be an HIV-negative male or female, aged 18 to 45 years old. Potential participants should have a history of receptive anal intercourse and be willing to be sexually abstinent for up to three days before each study visit, during product use, and for 3 days after biopsies for males and for 7 days after biopsies for females. Females able to become pregant will be required to use a medically acceptable form of contraception. Pregnant or lactating females will be ineligible for this study. Additonal inclusion/exclusion criteria applies. Compensation is provided after enrollment for those who qualify.

For more information or to see if you are eligible for this study, please contact us via phone or the web.

MTN 036 is a Phase I study.

The purpose of this study is to test the safety and pharmacokinetics of extended duration Dapivirine vaginal rings. Dapivirine is a new drug that was shown in recent studies to be safe and to help protect against HIV infection when applied vaginally. Participants in this study will wear the Dapivirine Vaginal Ring in a 25mg, 100mg, or 200mg dose for up to 90 days. Eligible volunteers will have 11 clinic visits during a 12 to 14 week period.

To qualify for this study, you need to be an HIV-negative female or transgender male, aged 18 to 45 years old. Potential participants should have regular menstrual cycles, be willing to use condoms as a contraceptive and protective method if sexually active and, be willing to be sexually abstinent 3 days before each visit and for 3 days after biopsies. Pregnant or lactating females will be ineligible for this study. Additonal inclusion/exclusion criteria applies. Compensation is provided after enrollment for those who qualify.

For more information or to see if you are eligible for this study, please contact us via phone or the web.

Reprieve is an AIDS Clinical Trial Group (ACTG) study for HIV positive men and women between the ages of 40 and 75. The purpose of this study is to see if pitavastatin, an FDA-approved drug for the treatment of high cholesterol, can prevent heart disease and heart disease related deaths in people with HIV infection who are also taking HIV medications.

To be eligible for this study, you must meet the age and HIV-status requirements, and you must also have been on antiretroviral therapy (ART) for at least six months prior to study entry. Women of childbearing potential must not be pregnant and agree not to participate in the conception process.

Those with a history of heart disease, current use of a -statin drug, or with a history of cancer within the past three years will not qualify. Additional exclusion criteria applies.

Compensation is provided after enrollment for those who qualify. If interested, please be aware that you will be in this study for up to six years. You will need to be seen in clinic for a screening visit, an entry visit, one month later, and then every four months.

For more information or to see if you qualify, contact us via phone or the web.

 
IMPrOVE (HPTN 083) is a Phase IIb/III HIV Prevention Trials Network efficacy study of quarterly injectable pre-exposure prophylaxis (PrEP) compared to daily oral Truvada as PrEP.

This study is open to HIV-negative cisgender (men who were born male and identify as male) men and transgender women who have sex with men and who are aged 18 or older. Participation in this study will last approximately 4 years with about 57 visits to the clinic.

For more information or to see if you are eligible for this study, please contact us via phone or the web.